Activity Stream
@moatrx
• 3 weeks ago
Posted a new blog:
US TYPE 2 DIABETES Competitive Intelligence
US TYPE 2 DIABETES Competitive Intelligence
Tirzepatide captured 41% of new GLP-1 starts in 12 months, while semaglutide's SELECT cardiovascular label reshapes a $22B US formulary landscape.
The US Type 2...
